Education
About Us
Working with TipRanks
Follow Us
arGEN X (GB:0QW0)
:0QW0
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
2.33Last Year’s EPS
-0.97Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 6.52%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, successful market expansion, and strategic pipeline advancements. However, financial challenges like foreign exchange losses and a full-year operating loss were noted. Overall, the positive aspects significantly outweighed the challenges.Company Guidance
During the recent call, significant guidance and metrics were provided regarding argenx's performance and future outlook. For the fiscal year 2024, the company reported product net sales of $2.2 billion, with a 98% year-over-year growth, driven by strong performance in MG and CIDP markets. The U.S. contributed $649 million to the quarterly sales, while Japan, the rest of the world, and China added $27 million, $49 million, and $12 million, respectively. Gross margins remained high at 90%, reflecting efficient supply chain management. For 2025, argenx anticipates becoming a profitable entity with an operating expense guidance of approximately $2.5 billion, marking a 25% increase year-over-year. The company plans to advance 10 Phase III studies and 10 proof-of-concept studies, aiming to further expand its product reach and drive innovation in the autoimmune space. Additionally, the anticipated FDA approval of VYVGART's prefilled syringe for self-administration is expected to further boost sales and patient convenience.Record-Breaking Revenue Growth
Product net sales for Q4 2024 were $737 million, with full-year sales at $2.2 billion, representing a 29% quarter-over-quarter growth and 98% growth compared to the same quarter in the previous year.
First Year of Profitability
2025 is expected to be the first year of profitability for argenx, marking a significant milestone driven by commercial success and disciplined innovation investment.
Expansion in the CIDP Market
argenx successfully launched VYVGART Hytrulo in the CIDP market, achieving early adoption and highlighting unmet needs in the community.
Robust Pipeline Advancements
The company advanced 10 Phase III studies and 10 proof-of-concept studies across its pipeline, emphasizing the broad potential of FcRn and C2 inhibitors.
---
GB:0QW0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0QW0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | €598.91 | €609.95 | +1.84% |
| Oct 31, 2024 | €513.16 | €529.63 | +3.21% |
| Jul 25, 2024 | €435.19 | €450.99 | +3.63% |
| May 09, 2024 | €367.38 | €336.89 | -8.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does arGEN X (GB:0QW0) report earnings?
arGEN X (GB:0QW0) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is arGEN X (GB:0QW0) earnings time?
arGEN X (GB:0QW0) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of arGEN X stock?
The P/E ratio of arGEN X is N/A.
What is GB:0QW0 EPS forecast?
GB:0QW0 EPS forecast for the fiscal quarter 2025 (Q1) is 2.33.
---